LivaNova saw the highest growth of 2.99% in patent filings in April and 1.66% in grants in May in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.99% and grants by 0.32%. GlobalData’s DataBook provides a comprehensive analysis of LivaNova‘s patent filings and grants. Buy the databook here.
LivaNova has been focused on protecting inventions in United States(US) with 13 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 80% filings and 45% grants. The United States(US), European Patent Office(EPO), and United Kingdom(GB) patent Office are among the top ten patent offices where LivaNova is filings its patents. Among the top granted patent authorities, LivaNova has 45% of its grants in United States(US), 36% in European Patent Office(EPO) and 18% in United Kingdom(GB).
Terumo and Fresenius Medical Care could be the strongest competitors for LivaNova
Patents related to healthtech and remote patient monitoring lead LivaNova's portfolio
LivaNova has the highest number of patents in healthtech followed by, remote patient monitoring and smart hospitals. For healthtech, nearly 33% of patents were filed and 67% of patents were granted in Q2 2024.
Cardiovascular devices related patents lead LivaNova portfolio followed by neurology devices, and nephrology and urology devices
LivaNova has highest number of patents in cardiovascular devices followed by neurology devices, nephrology and urology devices, other remote patient monitoring, and healthcare it. For cardiovascular devices, nearly 20% of patents were filed and 40% of patents were granted in Q2 2024.
For comprehensive analysis of LivaNova's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.